Vulvodynia – a multidisciplinary problem
https://doi.org/10.20538/1682-0363-2020-1-114-124
Abstract
This literature review is devoted to the problem of vulvodynia. The article summarizes information about the etiology and pathogenetic factors of this syndrome, touches the aspects of diagnosis and treatment of this form of chronic genital pain. Despite the prevalence of this pathology, women with pain in the vulva often remain undiagnosed and do not receive adequate therapeutic and psycho-emotional support. Currently, the focus is in searching of the definition, classification, prevalence, pathophysiological factors of occurrence and adequate personalized therapy of this nosology.
About the Authors
K. R. Bakhtiyarov
I.M. Sechenov First Moscow State Medical University;
Network of Family Medical Centers
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
P. V. Budanov
I.M. Sechenov First Moscow State Medical University;
Network of Family Medical Centers
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
V. A. Pronina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
Russian Federation
Build. 2, 8, Trubetskaya Str., Moscow, 119991, Russian Federation
E. V. Virivskaia
Network of Family Medical Centers
Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
Russian Federation
Build. 1, 5/2, Sergius Radonezhsky Str., Moscow, 107120, Russian Federation
References
1. Gansky S.A., Plesh O. Widespread pain and fibromyalgia in a biracial cohort of young women. J. Rheumatol. 2007; 34 (4): 810–817.
2. Thomas T.G. A Practical treatise upon the diseases of women. The American Journal of the Medical Sciences. 1879; 73 (155): 233–234. DOI: 10.1097/00000441-187907000-00038.
3. Reed B.D, Harlow S.D, Sen A., Edwards R.M., Chen D., Haefner H.K. Relationship between vulvodynia and chronic comorbid pain conditions. Obstet. Gynecol. 2012; 120 (1): 145–151. DOI: 10.1097/AOG.0b013e31825957cf.
4. Skene A.J. Diseases of the external organs of generation. Treatise on the diseases of women. New York: D Appleton & Co. 1888; 77–99.
5. Tribo M.J., Andio O., Ros S., Sen A. Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study. Dermatology. 2008; 216 (1): 24–30. DOI: 10.1159/000109354.
6. Moyal-Barracco M., Lynch P.J. 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. J. Reprod. Med. 2004; 49 (10): 772–777.
7. Khandker M., Brady S.S., Vitonis A.F., Maclehose R.F., Stewart E.G., Harlow B.L. The influence of depression and anxiety on risk of adult onset vulvodynia. J. Womens Health (Larchmt). 2011; 20 (10): 1445–1451. DOI: 10.1089/jwh.2010.2661.
8. Vieira-Baptista P., Lima-Silva J., Cavaco-Gomes J., Beires J. Prevalence of vulvodynia and risk factors for the condition in Portugal. International Journal of Gynecology & Obstetrics. 2014; 127 (3): 283–287. DOI: 10.1016/j.ijgo.2014.05.020.
9. Turk D.C., Dworkin R.H., Allen R.R., Bellamy N., Brandenburg N., Carr D.B., Cleeland C., Dionne R., Farrar J.T., Galer B.S., Hewitt D.J., Jadad A.R., Katz N.P., Kramer L.D., Manning D.C., McCormick C.G., McDermott M.P., McGrath P., Quessy S., Rappaport B.A., Robinson J.P., Royal M.A., Simon L., Stauffer J.W., Stein W., Tollett J., Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003; 106 (3): 337–345. DOI: 10.1016/j.pain.2003.08.001.
10. Basson R. The recurrent pain and sexual sequelae of provoked vestibulodynia: A perpetuating cycle. Sex. Med. 2012; 9 (8): 2077–2092. DOI: 10.1111/j.1743-6109.2012.02803.x.
11. Abramov L., Wolman I., David M.P. Vaginismus: an important factor in the evaluation and management of vulvar vestibulitis syndrome. Gynecol. Obstet. Invest. 1994; 38 (3): 194–197. DOI: 10.1159/000292478.
12. Hooker A.B., Moorst B.R., Haarst E.P., Ootegehem N.A., Dijken D.K., Heres M.H. Chronic pelvic pain: evaluation of the epidemiology, baseline demographics, and clinical variables via a prospective and multidisciplinary approach. Clin. Exp. Obstet. Gynecol. 2013; 40 (4): 492–498.
13. Haefner H.K. Vulvovaginal disease update vulvodynia. Durham. 2013.
14. Harlow B.L., Stewart E.G. A population-based assessment of chronic unexplained vulvar pain: Have we underestimated the prevalence of vulvodynia? J. Am. Mel. Womens Assoc. 2003; 58 (2): 82–88.
15. Gentilcore-Saulnier E., McLean L., Goldfinger C., Pukall C.F., Chamberlain S. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J. Sex. Med. 2010; 7 (2): 1003–1022. DOI: 10.1111/j.1743-6109.2009.01642. x.
16. Reed B.D., Harlow S.D., Sen A., Legocki L.J., Edwards R.M., Arato N., Haefner H.K. Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am. J. Obstet. Gynecol. 2012; 206 (2): 170.e1–170.9. DOI: 10.1016/j.ajog.2011.08.012.
17. Kandyba K., Binik Y.M. Hypnotherapy as a treatment for vulvar vestibulitis syndrome: a case report. J. Sex. Marital. Ther. 2003; 29 (3): 237–242. DOI: 10.1080/00926230390155122.
18. Metts J.F. Vulvodynia and vulvar vestibulitis: challenges in diagnosis and management. Am. Fam Physician. 1999; 59 (6): 1547–1562.
19. Schlaeger J.M., Xu N., Mejta C.L., Park C.G., Wilkie D.J. Acupuncture for the treatment of vulvodynia: a Randomized Wait-List Controlled Pilot Study. J. Sex. Med. 2015; 12 (4): 1019–1027. DOI: 10.1111/jsm.12830.
20. Nguyen R.H., Swanson D., Harlow B.L. Urogenital infections in relation to the occurrence of vulvodynia. J. Reprod. Med. 2009; 54 (6): 385–392.
21. Coady D., Futterman S., Harris D., Coleman S.H. Vulvodynia and concomitant femoro-acetabular impingement. Journal of Lower Genital Tract Disease. 2015; 19 (3): 253–256. DOI: 10.1097/LGT.0000000000000108.
22. Harlow B.L., Kunitz C.G., Nguyen R.H.N., Rydell S.A., Turner R.M., MacLehose R.F. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. Am. J. Obstet. Gynecol. 2014; 210 (1): 40.e1–40.8. DOI: 10.1016/j.ajog.2013.09.033.
23. Donders G.G., Bellen G. Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: a Double-Blind Randomized Placebo-Controlled Crossover Study. J. Low Genital. Tract Dis. 2012; 16 (4): 12–16. DOI: 10.1097/LGT.0b013e31825a2274.
24. Reed B.D., Legocki L.J., Plegue M.A., Sen A., Haefner H.K., Harlow S.D. Factors associated with vulvodynia incidence. Obstetrics & Gynecology. 2014; 123 (2, Pt 1): 225–231. DOI: 10.1097/AOG.0000000000000066.
25. Ventolini G. Measuring treatment outcomes in women with vulvodynia. J. Clin. Med. Res. 2011; 3 (2): 59–64. DOI: 10.4021/jocmr526w.
26. Eastwood J., Johnson B.D., Rutledge T. et al. Anginal symptoms, coronary artery disease, and adverse outcomes in black and white women: The NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study. J. Womens Health. 2013; 22 (9): 724–732. DOI: 10.1089/jwh.2012.4031.
27. Brown C.S., Wan J., Bachmann G., Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J. Womens Health (Larchmt). 2009; 18 (2): 163–169. DOI: 10.1089/jwh.2007.0676 .
28. Groysman V. Vulvodynia: new concepts and review of the literature. Dermatol. Clin. 2010; 28 (4): 681–696. DOI: 10.1016/j.det.2010.07.002.
29. Foster D.C., Kotok M.B., Huang L.S., Watts A., Oakes D., Howard F.M., Poleshuck E.L., Stodgell C.J., Dworkin R.H.. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet. Gynecol. 2010; 116 (3): 583–593. DOI: 10.1097/AOG.0b013e3181e9e0ab.
30. Gardella B., Porru D., Nappi R.E., Daccò M.D., Chiesa A., Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction – a Case Control Study. J. Sex. Med. 2011; 8: 1726–1734. DOI: 10.1111/j.1743-6109.2011.02251.x.
31. Meltzer-Brody S.E., Zolnoun D., Steege J.F., Rinaldi K.L., Leserman J. Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J. Reprod. Med. 2009; 54 (3): 171–178.
32. McCormack W.M. Two urogenital sinus syndromes. Interstitial cystitis and focal vulvitis. J. Reprod. Med. 1990; 35 (9): 873–876.
33. Fitzpatrick C.C., DeLancey J.O., Elkins T.E. et al. Vulvar vestibulitis and interstitial cystitis; a disorder of urogenital sinus-derived epithelium. Obstet. Gynecol. 1993; 81 (5): 860–862.
34. Goetsch M.F. Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am. J. Obstet. Gynecol. 1991; 164 (6 Pt 1): 1609–1614. DOI: 10.1016/0002-9378(91)91444-2.
35. Foster D.C., Piekarz K.H., Murant T.I., LaPoint R., Haidaris C.G., Phipps R.P. Enhanced synthesis of pro inflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis. Am. J. Obstet. Gynecol. 2007; 196 (4): 346.e1–8. DOI: 10.1016/j.ajog.2006.12.038.
36. Bohm-Starke N., Hilliges M., Falconer C., Rylander E. Increased intraepithelial innervation in women with vulvar vestibulitis syndrome. Gynecol. Obstet. Invest. 1998; 46 (4): 256–260. DOI: 10.1159/000010045.
37. Tympanidis P., Terenghi G., Dowd P. Increased innervation of the vulvar vestibule in patients with vulvodynia. Br. J. Dermatol. 2003; 148 (5): 1021–1027. DOI: 10.1046/j.1365-2133.2003.05308.x.
38. Westrom L.V., Wille´n R. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet. Gynecol. 1998; 91 (4): 572–576.
39. Krantz K.E. Innervation of the human vulva and vagina; a microscopic study. Obstet. Gynecol. 1958; 12 (4): 382–396.
40. Heddini U., Bohm-Starke N., Nilsson K.W., Johannesson U. Provoked vestibulodynia – medical factors and comorbidity associated with treatment outcome. J. Sex. Med. 2012; 9 (5): 1400–1406. DOI: 10.1111/j.1743-6109.2012.02665.x.
41. Foster D.C., Sazenski T.M., Stodgell C.J. Impact of genital variation in interleukin-1 receptor antagonist and melanocortin-1 receptor genes on vulvar vestibulitis syndrome. J. Reprod. Med. 2004; 49 (7): 503–509.
42. Hampson J.P., Reed B.D., Clauw D.J., Bhavsar R., Gracely R.H., aefner H.K., Harris R.E. Augmented central pain processing in vulvodynia. Pain. 2013; 14 (6): 579–589. DOI: 10.1016/j.jpain.2013.01.767.
43. Pukall C.F., Binik Y.M., Khalifé S., Amsel R., Abbott F.V. Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. Pain. 2002; 96 (1–2): 163–175. DOI: 10.1016/s0304-3959(01)00442-0.
44. Tympanidis P., Casula M.A., Yiangou Y., Terenghi G., Dowd P., Anand P. Increased vanilloid receptor VR1 innervation in vulvodynia. Eur. J. Pain. 2004; 8 (2): 129–133. DOI: 10.1016/S1090-3801(03)00085-5.
45. Babula O., Danielsson I., Sjoberg I., Ledger W.G. Altered distribution of mannose-binding lectin alleles at exon I codon 54 in women with vulvar vestibulitis syndrome. Am. J. Obstet. Gynecol. 2004; 191 (3): 762–766. DOI: 10.1016/j.ajog.2004.03.073.
46. Lev-Sagie A., Prus D., Linhares I.M., Nyberg F., Nilsson K.W., Johannesson U. Polymorphism in a gene coding for the inflammasome component NALP3 and recurrent vulvovaginal candidiasis in women with vulvar vestibulitis syndrome. Am. J. Obstet. Gynecol. 2009; 200 (3): 303.e1–6. DOI: 10.1016/j.ajog.2008.10.039.
47. Gerber S., Bongiovanni A.M., Ledger W.J., Witkin S.S. Interleukin-1b gene polymorphism in women with vulvar vestibulitis syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003; 107 (1): 74–77. DOI: 10.1016/s0301-2115(02)00276-2.
48. Goldstein A.T., Belkin Z.R., Krapf J.M., Song W., Khera M., Jutrzonka S.L., Kim N.N., Burrows L.J., Goldstein I. Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J. Sex. Med. 2014; 11 (11): 2764–2771. DOI: 10.1111/jsm.12668.
49. Johannesson U., de Boussard C.N., Brodda Jansen G., Bohm-Starke N. Evidence of diffuse noxious inhibitory controls (DNIC) elicited by cold noxious stimulation in patients with provoked vestibulodynia. Pain. 2007; 13 (1–2): 31–39. DOI: 10.1016/j.pain.2006.10.022.
50. Meczekalski B., Podfigurna-Stopa A., Warenik-Szymankiewicz A., Genazzani A.R. Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations. Gynecol. Endocrinol. 2008; 24 (1): 4–11. DOI: 10.1080/09513590701807381.
51. Siddle N., Sarrel P., Whitehead M. The effect of hysterectomy on the age at ovarian failure: Identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril. 1987; 47 (1): 94–100. DOI: 10.1016/s0015-0282(16)49942-5.
52. Burrows L.J., Basha M., Goldstein A.T. The effects of hormonal contraceptives on female sexuality: a review. J. Sex. Med. 2012; 9 (9): 2213–2223. DOI: 10.1111/j.1743-6109.2012.02848.x.
53. Bohm-Starke N., Johannesson U., Hilliges M., Rylander E., Torebjörk E. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? J. Reprod. Med. 2004; 49 (11): 888–892.
54. Battaglia C., Morotti E., Persico N., Battaglia B., Busacchi P., Casadio P., Paradisi R., Venturoli S. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. J. Sex. Med. 2014; 11 (2): 471–480. DOI: 10.1111/jsm.12392.
55. Bazin S., Bouchard C., Brisson J., Morin C., Meisels A., Fortier M. Vulvar vestibulitis syndrome: an exploratory case-control study. Obstet. Gynecol. 1994; 83 (11): 47–50.
56. Bouchard C., Brisson J., Fortier M., Morin C., Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am. J. Epidemiol. 2002; 156 (93): 254–261. DOI: 10.1093/aje/kwf037.
57. Harlow B.L., Vitonis A.F., Stewart E.G. Influence of oral contraceptive use on the risk of adult-onset vulvodynia. J. Reprod. Med. 2008; 53 (2): 102–110.
58. Greenstein A., Ben-Aroya Z., Fass O., Militscher I., Roslik Y., Chen J., Abramov L. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J. Sex. Med. 2007; 4 (6): 1679–1683. DOI: 10.1111/j.1743-6109.2007.00621.x.
59. Burrows L.J., Goldstein A.T. The treatment of vestibulodynia with topical estradiol and testosterone. Sex. Med. 2013; 1 (1): 30–33. DOI: 10.1002/sm2.4.
60. Edwards L. Vulvodynia. Clinical Obstetrics and Gynecology. 2015; 58 (1): 143–152. DOI: 10.1097/GRF.0000000000000093.
61. Reed B.D., Harlow S.D., Legocki L.J., Helmuth M.E., Haefner H.K., Gillespie B.W., Sen A. Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study. BJOG. 2013; 120 (13): 1678–1684. DOI: 10.1111/1471-0528.12407.
62. Haefner H.K., Collins M.E., Davis G.D., Edwards L., Foster D.C., Hartmann E.H., Kaufman R.H., Lynch P.J., Margesson L.J., Moyal-Barracco M., Piper C.K., Reed B.D., Stewart E.G., Wilkinson E.J. The vulvodynia guideline. J. Low Genit. Tract Dis. 2005; 9 (1): 40–51. DOI: 10.1097/00128360-200501000-00009.
63. LeClair C., Goetsch M., Korcheva V., Anderson R., Peters D., Morgan T.K. Differences in primary compared with secondary vestibulodynia by immunohistochemistry. Obstet. Gynecol. 2011; 117 (6): 1307–16313. DOI: 10.1097/AOG.0b013e31821c33dc.
64. Shah M., Hoffstetter S. Vulvodynia. Obstetrics and Gynecology Clinics of North America. 2014; 41 (3): 453–464. DOI: 10.1016/j.ogc.2014.05.005.
65. Sadownik L.A. Clinical profile of vulvodynia patients. A prospective study of 300 patients. J. Reprod. Med. 2000; 45 (8): 679–684.
66. Brown C.S., Foster D.C., Bachour C.C., Rawlinson L.A., Wan J.Y., Bachmann G.A. Presenting symptoms among black and white women with provoked vulvodynia. J.Womens Health (Larchmt). 2015; 24 (10): 831–836. DOI: 10.1089/jwh.2014.5164.
67. Gansky S.A., Plesh O. Widespread pain and fibromyalgia in a biracial cohort of young women. J. Rheumatol. 2007; 34 (4): 810–817.
68. Reed B.D, Harlow S.D, Sen A., Edwards R.M., Chen D., Haefner H.K. Relationship between vulvodynia and chronic comorbid pain conditions. Obstet. Gynecol. 2012; 120 (1): 145–151. DOI: 10.1097/AOG.0b013e31825957cf.
69. Tribo M.J., Andio O., Ros S., Sen A. Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study. Dermatology. 2008; 216 (1): 24–30. DOI: 10.1159/000109354.
70. Khandker M., Brady S.S., Vitonis A.F., Maclehose R.F., Stewart E.G., Harlow B.L. The influence of depression and anxiety on risk of adult onset vulvodynia. J. Womens Health (Larchmt). 2011; 20 (10): 1445–1451. DOI: 10.1089/jwh.2010.2661.
71. Turk D.C., Dworkin R.H., Allen R.R., Bellamy N., Brandenburg N., Carr D.B., Cleeland C., Dionne R., Farrar J.T., Galer B.S., Hewitt D.J., Jadad A.R., Katz N.P., Kramer L.D., Manning D.C., McCormick C.G., McDermott M.P., McGrath P., Quessy S., Rappaport B.A., Robinson J.P., Royal M.A., Simon L., Stauffer J.W., Stein W., Tollett J., Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003; 106 (3): 337–345. DOI: 10.1016/j.pain.2003.08.001.
72. Abramov L., Wolman I., David M.P. Vaginismus: an important factor in the evaluation and management of vulvar vestibulitis syndrome. Gynecol. Obstet. Invest. 1994; 38 (3): 194–197. DOI: 10.1159/000292478.
73. Haefner H.K. Vulvovaginal disease update vulvodynia. Durham. 2013.
74. Gentilcore-Saulnier E., McLean L., Goldfinger C., Pukall C.F., Chamberlain S. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J. Sex. Med. 2010; 7 (2): 1003–1022. DOI: 10.1111/j.1743-6109.2009.01642. x.
75. Kandyba K., Binik Y.M. Hypnotherapy as a treatment for vulvar vestibulitis syndrome: a case report. J. Sex. Marital. Ther. 2003; 29 (3): 237–242. DOI: 10.1080/00926230390155122.
76. Schlaeger J.M., Xu N., Mejta C.L., Park C.G., Wilkie D.J. Acupuncture for the treatment of vulvodynia: a Randomized Wait-List Controlled Pilot Study. J. Sex. Med. 2015; 12 (4): 1019–1027. DOI: 10.1111/jsm.12830.
77. Coady D., Futterman S., Harris D., Coleman S.H. Vulvodynia and concomitant femoro-acetabular impingement. Journal of Lower Genital Tract Disease. 2015; 19 (3): 253–256. DOI: 10.1097/LGT.0000000000000108.
78. Donders G.G., Bellen G. Cream with cutaneous fibroblast lysate for the treatment of provoked vestibulodynia: a Double-Blind Randomized Placebo-Controlled Crossover Study. J. Low Genital. Tract Dis. 2012; 16 (4): 12–16. DOI: 10.1097/LGT.0b013e31825a2274.
79. Ventolini G. Measuring treatment outcomes in women with vulvodynia. J. Clin. Med. Res. 2011; 3 (2): 59–64. DOI: 10.4021/jocmr526w.
80. Brown C.S., Wan J., Bachmann G., Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J. Womens Health (Larchmt). 2009; 18 (2): 163–169. DOI: 10.1089/jwh.2007.0676 .
81. Foster D.C., Kotok M.B., Huang L.S., Watts A., Oakes D., Howard F.M., Poleshuck E.L., Stodgell C.J., Dworkin R.H.. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet. Gynecol. 2010; 116 (3): 583–593. DOI: 10.1097/AOG.0b013e3181e9e0ab.
82. Meltzer-Brody S.E., Zolnoun D., Steege J.F., Rinaldi K.L., Leserman J. Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J. Reprod. Med. 2009; 54 (3): 171–178.
Review
For citations:
Bakhtiyarov K.R., Budanov P.V., Pronina V.A., Virivskaia E.V. Vulvodynia – a multidisciplinary problem. Bulletin of Siberian Medicine. 2020;19(1):114-124. https://doi.org/10.20538/1682-0363-2020-1-114-124
Views:
976
Email this article 